The global potent active pharmaceutical ingredients (HPAPIs) market to reach nearly USD 18.5 Billion in 2020, at a CAGR of 6.2% from 2016 to 2020, majorly due to patent expiry of blockbuster drugs and growing trend in pharmaceutical outsourcing.
Browse Highly Potent Active Pharmaceutical Ingredients Market by API (Biological, Chemical), Drugs (Branded, Generic, OTC), Manufacturing (In-House, Outsourcing or Contact-Based), Therapeutic Area (Diabetes, Cardiovascular, CNS, Oncology, Musculoskeletal Drugs) 2016-2020 report at https://www.ihealthcareanalyst.com/report/high-potency-active-pharmaceutical-ingredient-market/
Highly potent active pharmaceutical ingredients (HPAPIs) represent a significant change in the way pharmaceutical innovators are using small molecules to deliver new patient therapies. The shift toward highly potent APIs has not only led to a pipeline of more effective medicines that require lower doses and lead to fewer side effects, but also to new manufacturing challenges. During the last decade, the demand for HPAPIs has grown rapidly, mainly as a result of advances in clinical pharmacology and oncology research. HPAPIs drug manufacturing, storage and packaging is subject to Current Good Manufacturing Process (cGMP) regulations enforced by the U.S. FDA, EMEA and other international regulatory agencies. Contract manufacturing of HPAPI has been preferred over captive production due to high degree of competition and reduced profitability, geographical advantage and cost-effectiveness.
The global highly potent active pharmaceutical ingredients (HPAPIs) market report estimates the market size (Revenue USD million – 2013 to 2020) for key market segments based on the API (biological, chemical), drug (branded, generic, OTC), manufacturing (in-house, outsourcing or contact-based), therapeutic area (diabetes, cardiovascular, CNS, oncology, musculoskeletal drugs, etc.), and forecasts growth trends (CAGR% – 2016 to 2020). The global highly potent active pharmaceutical ingredients market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global highly potent active pharmaceutical ingredients market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global highly potent active pharmaceutical ingredients (HPAPIs) market and included in this report are Alkermes plc, Cambrex Corporation, Dr. Reddy’s Laboratories, Lonza Group, Novasep, Sandoz International GmbH, Pfizer, Inc., Sigma-Aldrich Co. LLC, and WuXi AppTec.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/high-potency-active-pharmaceutical-ingredient-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043